Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
A historical perspective: Are inhaled corticoids sufficient to control asthma?
TL;DR: Inhaled corticoids made a dramatic breakthrough in the management of asthma in the late eighties resulting in a sharp reduction in morbidity and mortality in the following decades, and the association between ICS and long acting β2 agonists (LABA) soon became the gold standard of maintenance asthma treatment.
Journal ArticleDOI
Omalizumab for the treatment of severe allergic asthma
TL;DR: The evidence for both clinical and cost–effectiveness of omalizumab in patients with severe asthma is examined and a 5-year view on the likely role of o malizumAB in clinical practice is given.
Клиническо-экономический анализ лечения взрослых пациентов с тяжелой аллергической эозинофильной бронхиальной астмой: меполизумаб и омализумаб
Толкушин Александр Геннадьевич,Погудина Наталья Леонидовна,Иванов Дмитрий Андреевич,Демко Ирина Владимировна +3 more
TL;DR: This document is intended to help clarify the role that language plays in the decision-making process in the case of plagiarism.
Journal ArticleDOI
Du phénotype clinique aux mécanismes traitables dans les maladies allergiques/atopiques : asthme et rhinite
TL;DR: In this paper, the authors present a vision phenotypique of l’asthme and the rhinite allergique, which are the pathologies respiratoires les plus frequentes.
Dissertation
Activation of the Epithelial Mesenchymal Trophic Unit (EMTU) and markers of remodelling associated with asthma persistence and remission in early adulthood
TL;DR: Compared markers of remodelling, inflammation and epithelial repair in young adults recruited from the well-established 1989 Isle of Wight Birth Cohort, to determine the similarities and differences between those young adults who had grown out of their childhood asthma and those who had not.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.